Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.49 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13640821 | 0.90 | SIGMAR1 (0.47) | SIGMAR1SLC18A3KCNH2HSD11B1OPRM1 | |
| SCHEMBL13641009 | 0.86 | SIGMAR1 (0.49) | SIGMAR1SLC18A3DRD2HSD11B1 | |
| SCHEMBL13640903 | 0.86 | SIGMAR1 (0.51) | SIGMAR1SLC18A3KCNH2HSD11B1OPRM1 | |
| SCHEMBL13640806 | 0.85 | SIGMAR1 (0.50) | SIGMAR1SLC18A3KCNH2HSD11B1OPRM1 | |
| SCHEMBL13640752 | 0.83 | MAPT (0.41) | DRD2KCNH2GRIN2BOPRL1LMNA | |
| SCHEMBL13641011 | 0.82 | SIGMAR1 (0.47) | SIGMAR1SLC18A3KCNH2HSD11B1OPRM1 | |
| SCHEMBL13640802 | 0.82 | SIGMAR1 (0.47) | SIGMAR1SLC18A3KCNH2HSD11B1OPRM1 | |
| SCHEMBL13640768 | 0.81 | NOTUM (0.50) | SIGMAR1SLC18A3DRD2KCNH2GRIN2B | |
| SCHEMBL13641024 | 0.81 | MCHR2 (0.46) | DRD2KCNH2GRIN2BLMNAMAPT | |
| SCHEMBL13640993 | 0.81 | MCHR2 (0.46) | DRD2KCNH2GRIN2BLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497295-B2 | Spiroindoline modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | CHRM3, CHRM2, CHRM5 | SIGMAR1 253/4885SLC18A3 319/4885DRD2 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.